INAB
IN8BIO, INC.
$1.66
-0.89%
$16.5M
No data for this timeframe.
Vol
Market Cap$16.5M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders4 funds
Inst. Value$132.5K
Inst. Activity0 buys / 2 sells
Reddit Sentiment64° Warm
SEC Reports3
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001740279·Prev Close $1.68
Recent Activity
May 18, 2026
SEC
IN8bio filed Amendment No. 1 to its existing S-3 shelf registration, maintaining the $200M aggregate offering capacity f
S-3/A — Impact 7/10
May 9, 2026
Insider
Epperly Corinne sold 22,000 shares
Director @ $0.00 ($0.00)
May 9, 2026
Insider
Greenwood Luba sold 22,000 shares
Director @ $0.00 ($0.00)
May 9, 2026
Insider
Ho William Tai-Wei sold 154,500 shares
CEO @ $0.00 ($0.00)
May 7, 2026
SEC
IN8bio reported Q1 2026 net loss of $5.1M ($0.26 per share), beating the -$0.59 consensus, driven by lower R&D expenses.
8-K — Impact 3/10
Mar 26, 2026
SEC
IN8BIO, INC. filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting of Stockholders, scheduled for May
DEFA14A — Impact 3/10
Inst.
VANGUARD GROUP INC — TRIM
28,348 shares ($66.3K)
Inst.
TWO SIGMA INVESTMENTS, LP — TRIM
28,214 shares ($66.0K)
Price Targets
$6.25
+275.4% upside
Strong Buy
Current $1.67
Low $4.00
Median $5.50
High $10.00
4 analysts
$4.00
$10.00
Analyst Ratings
2Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 13, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.37 ▲ +48.9% | $-0.61 — $-0.24 | 70% YoY | 3 |
| Next Q | $-0.38 ▲ +42.0% | $-0.69 — $-0.21 | 55% YoY | 3 |
| Current FY | $-1.24 ▲ +50.2% | $-2.10 — $-0.87 | 72% YoY | 4 |
| Next FY | $-1.06 ▲ +29.7% | $-1.51 — $-0.68 | 15% YoY | 4 |
Latest Reports
BEARISH
S-3/A
7/10
IN8bio filed Amendment No. 1 to its existing S-3 shelf registration, maintaining the $200M aggregate offering capacity f
May 18, 2026
NEUTRAL
8-K
3/10
IN8bio reported Q1 2026 net loss of $5.1M ($0.26 per share), beating the -$0.59 consensus, driven by lower R&D expenses.
May 7, 2026
BULLISH
Press
8/10
IN8bio reported strong clinical data in glioblastoma showing a 97% improvement in median progression-free survival with
Mar 12, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $66.3K | TRIM |
| TWO SIGMA INVESTMENTS, LP | $66.0K | TRIM |
| BANK OF AMERICA CORP | $87.00 | ADD |
| MORGAN STANLEY | $80.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 9, 2026 | Epperly Corinne | A | $0.00 |
| May 9, 2026 | Greenwood Luba | A | $0.00 |
| May 9, 2026 | Ho William | A | $0.00 |
| May 9, 2026 | Lamb Lawrence | A | $0.00 |
| May 9, 2026 | FAIRBAIRN EMILY | A | $0.00 |
Reddit Sentiment
64°
Warm
Bearish
Neutral
Bullish
4 institutional holders with $132.5K total value (56,633 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, BANK. Net selling activity: 2 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 28,348 | $66.3K | 50.1% | TRIM -52.3% |
| 2 | TWO SIGMA INVESTMENTS, LP | 28,214 | $66.0K | 49.8% | TRIM -42.9% |
| 3 | BANK OF AMERICA CORP /DE/ | 37 | $87.00 | 0.1% | ADD +50.0% |
| 4 | MORGAN STANLEY | 34 | $80.00 | 0.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | TRIM | 59,418 | 28,348 | -52.3% | $66.3K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 49,453 | 28,214 | -42.9% | $66.0K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 49,453 | — | $107.3K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 24 | 36 | +50.0% | $78.00 | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 479 | 15 | -96.9% | $32.00 | 2025-Q3 |
| VANGUARD GROUP INC | NEW | — | 60,097 | — | $125.6K | 2025-Q2 |
| VANGUARD GROUP INC | EXIT | 1,802,956 | 0 | -100.0% | $0.00 | 2025-Q2 |
| VANGUARD GROUP INC | ADD | 1,423,897 | 1,802,956 | +26.6% | $299.3K | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 58,853 | 12,327 | -79.1% | $2.0K | 2025-Q1 |
| UBS Group AG | DOUBLED | 26,270 | 58,853 | +124.0% | $15.1K | 2024-Q4 |
7 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 9, 2026 | Epperly Corinne | Director | A | 22,000 | $0.00 | $0.00 |
| May 9, 2026 | Greenwood Luba | Director | A | 22,000 | $0.00 | $0.00 |
| May 9, 2026 | Ho William Tai-Wei | CEO | A | 154,500 | $0.00 | $0.00 |
| May 9, 2026 | Lamb Lawrence | EVP and CSO | A | 54,000 | $0.00 | $0.00 |
| May 9, 2026 | FAIRBAIRN EMILY | Director | A | 22,000 | $0.00 | $0.00 |
| May 9, 2026 | McCall Patrick | CHIEF FINANCIAL OFFICER | A | 56,250 | $0.00 | $0.00 |
| May 9, 2026 | Rochlin Kate | President and COO | A | 60,000 | $0.00 | $0.00 |
| Feb 4, 2026 | Rochlin Kate | President and COO | A | 80,000 | $0.00 | $0.00 |
| Feb 4, 2026 | McCall Patrick | CHIEF FINANCIAL OFFICER | A | 75,000 | $0.00 | $0.00 |
| Feb 4, 2026 | Lamb Lawrence | EVP and CSO | A | 72,000 | $0.00 | $0.00 |
| Feb 4, 2026 | Ho William Tai-Wei | CEO | A | 206,000 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 4.3/10.
BEARISH
S-3/A
7/10
IN8bio filed Amendment No. 1 to its existing S-3 shelf registration, maintaining the $200M aggregate
May 18, 2026
NEUTRAL
8-K
3/10
IN8bio reported Q1 2026 net loss of $5.1M ($0.26 per share), beating the -$0.59 consensus, driven by
May 7, 2026
NEUTRAL
DEFA14A
3/10
IN8BIO, INC. filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting of Stockholder
Mar 26, 2026
Current analyst consensus: Strong Buy (90% buy). Based on 10 analysts: 2 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$6.25 mean target
+275.4% upside
Strong Buy (1.25)
$4.00 Low
$10.00 High
| Metric | Value |
|---|---|
| Current Price | $1.67 |
| Target Low | $4.00 |
| Target Mean | $6.25 |
| Target Median | $5.50 |
| Target High | $10.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (1.25) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.37 | $-0.61 | $-0.24 | 69.9% | +48.9% | — | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.38 | $-0.69 | $-0.21 | 55.3% | +42.0% | — | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-1.24 | $-2.10 | $-0.87 | 72.0% | +50.2% | 2↑ 1↓ | $0.0B | 0.0% | 4 |
| Next FY 2027-12-31 |
$-1.06 | $-1.51 | $-0.68 | 14.7% | +29.7% | 2↑ 1↓ | $0.0B | 0.0% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.373 | |
| 7d ago | $-0.730 | +0.357 |
| 30d ago | $-0.730 | +0.357 |
| 60d ago | $-0.255 | -0.118 |
| 90d ago | $-0.255 | -0.118 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 13, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Jan 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
64°
Warm
Bearish
Neutral
Bullish
3 mentions
2 bullish
0 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 6, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 6, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 26, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
May 7, 2026
earnings
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 6, 2026
other
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
May 4, 2026
earnings_calendar
INAB Q1 2026 Earnings Scheduled — 2026-05-04
May 1, 2026
earnings_calendar
INAB Q1 2026 Earnings Scheduled — 2026-05-01
Apr 3, 2026
other
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mar 12, 2026
earnings
IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026
IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results
Mar 2, 2026
earnings_calendar
INAB Q4 2025 Earnings After Market Close — 2026-03-02